ProBioGen
Latest round
- Series B
Last raised
- Jun 2003
Total raised
- $5.2M
Investors
- 3
About ProBioGen
ProBioGen AG operates as a contract development and manufacturing organization (CDMO) in the biopharmaceutical sector, with its headquarters located in Berlin, Germany. The company was acquired by Minapharm Pharmaceuticals, which now holds a 95% stake as of June 16, 2010, marking a pivotal shift in ownership. The leadership team includes Lutz Hilbrich, Marc Bantel, and Wieland Wolf.ProBioGen AG specializes in providing comprehensive Contract Development and Manufacturing Organization (CDMO) services tailored for the biopharmaceutical sector. Their core offerings encompass cell line engineering, process development, and Good Manufacturing Practice (GMP) manufacturing, focusing on biopharmaceuticals, viral vectors, and vaccines.RiGHT® for producer cell lines and DirectedLuck® for transposase systems, ProBioGen optimizes the manufacturing processes to enhance product yield and quality. The company caters to a diverse client base that includes biotechnology and pharmaceutical firms globally, particularly in regions such as North America, Europe, and Asia.20. The firm's revenue generation relies on customized service agreements that may include project-based pricing for specific development and manufacturing services, as well as ongoing collaborations for extended projects. Their framework for transactions often involves upfront fees coupled with milestone payments based on the successful completion of defined project stages.RiGHT® production system and GMP manufacturing capabilities for viral vaccines, command premium pricing due to their specialized nature and the high demand for reliable biopharmaceutical development.ProBioGen AG is focused on enhancing its product offerings, with plans for the development of new biopharmaceutical manufacturing technologies aimed at improving efficiency and yields. The company is also looking to expand its reach into emerging markets in Asia and South America by 2025, capitalizing on the growing demand for biopharmaceuticals in these regions. The strategic acquisition by Minapharm Pharmaceuticals positions ProBioGen to leverage additional resources and expertise to accelerate its growth trajectory.
Who invested in ProBioGen
3 investors across 1 round
See all investors in ProBioGen
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series B
Jun 12, 2003
Amount
$5.2M
Investors
Questions about ProBioGen
Who invested in ProBioGen?
ProBioGen has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has ProBioGen raised?
ProBioGen has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did ProBioGen last raise money?
ProBioGen's most recent round on record is a Series B, in Jun 2003.
What does ProBioGen do?
ProBioGen AG operates as a contract development and manufacturing organization (CDMO) in the biopharmaceutical sector, with its headquarters located in Berlin, Germany.
Where is ProBioGen headquartered?
ProBioGen is headquartered in Berlin, Germany.
Which VCs invest in companies like ProBioGen?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at ProBioGen's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like ProBioGen? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.